Cetera Investment Advisers
CLDX icon

Cetera Investment Advisers’s Celldex Therapeutics CLDX Stock Holding History

Cetera Investment Advisers’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Buy
7,288
+92
+1% +$2.97K ﹤0.01% 4241
2026
Q1 		$228K Sell
7,196
-2,699
-27% -$73.6K ﹤0.01% 4192
2025
Q4 		$269K Sell
9,895
-10
-0.1% -$263 ﹤0.01% 4000
2025
Q3 		$256K Buy
+9,905
New +$230K ﹤0.01% 3969

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cetera Investment Advisers's CLDX Position: Q2 2026 in Review

Cetera Investment Advisers increased its Celldex Therapeutics (CLDX) stake by 1.3% in Q2 2026, buying an estimated $2.97K and bringing the position to 7,288 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #4241.

Cetera Investment Advisers first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Cetera Investment Advisers held 7,288 shares of Celldex Therapeutics worth $271K as of Q2 2026.
  • Cetera Investment Advisers bought 92 Celldex Therapeutics shares in Q2 2026, an estimated $2.97K.
  • Celldex Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4241 holding.
  • Cetera Investment Advisers first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.